Skip to main content
Article thumbnail
Location of Repository

Good laboratory practice: preventing introduction of bias at the bench

By Malcolm R. Macleod, Marc Fisher, Victoria O'Collins, Emily S. Sena, Ulrich Dirnagl, Philip M.W. Bath, Alistair Buchan, H. Bart van der Worp, Richard Traystman, Kazuo Minematsu, Geoffrey A. Donnan and David W. Howells


Background and Purpose—As a research community, we have failed to demonstrate that drugs which show substantial\ud efficacy in animal models of cerebral ischemia can also improve outcome in human stroke.\ud \ud Summary of Review—Accumulating evidence suggests this may be due, at least in part, to problems in the design, conduct\ud and reporting of animal experiments which create a systematic bias resulting in the overstatement of neuroprotective\ud efficacy.\ud \ud Conclusions—Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal\ud experiments modeling human stroke

Publisher: American Heart Association Inc
Year: 2009
OAI identifier:
Provided by: Nottingham ePrints

Suggested articles


  1. (2006). 1,026 experimental treatments in acute stroke. Ann Neurol.
  2. (2009). Bench to bedside: the quest for quality in experimental stroke research. doi
  3. Does the consort checklist improve the quality of reports of randomised controlled trials? A systematic review.
  4. (2008). Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke.
  5. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality.
  6. (2007). How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci.
  7. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis.
  8. Improving the quality of reporting of randomized controlled trials. The consort statement. doi
  9. Quality of full and final publications reporting acute stroke trials: a systematic review.
  10. (1999). Recommendations for standards regarding preclinical neuroprotective and restorative drug development.
  11. Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome.
  12. Systematic review and metaanalysis of the efficacy of fk506 in experimental stroke.
  13. The revised consort statement for reporting randomized trials: Explanation and elaboration.
  14. Why do all drugs work in animals but none in stroke patients?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.